改善认知而不清除粉样蛋白:陶氏和超声波神经调节的影响
Gerhard Leinenga1, Pranesh Padmanabhan1,2, Jürgen Götz1
1Clem Jones Centre for Ageing Dementia Research (CJCADR), Queensland Brain Institute (QBI), The University of Queensland, Brisbane, QLD, Australia.
Journal of Alzheimer's disease : JAD
|July 26, 2024
概括
阿尔茨海默病涉及蛋白质的积累,如粉样β (Aβ) 和tau. 新的研究表明,认知功能可以独立于Aβ降低来改善,这表明了替代治疗点.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是神经元功能障碍,损失和痴呆的进展.
- 蛋白质聚合,包括细胞外粉样β (Aβ) 斑块和细胞内团,是AD病理学的标志.
- 传统的观点认为,Aβ在线性级联,并驱动tau病理和认知衰退.
研究的目的:
- 在阿尔茨海默氏病模型中调查粉样β (Aβ) 负担和认知功能之间的关系.
- 探索可以将Aβ病理与认知结果分离的治疗策略.
- 检查非粉样蛋白向干预措施改善AD认知的潜力.
主要方法:
- 对有关阿尔茨海默氏症病原和治疗干预措施的现有文献的综述.
- 对证明Aβ降低和tau操纵效应的临床前模型的分析.
- 考虑涉及低强度超声波作为神经调节方法的研究.
主要成果:
- 降低Aβ负载可以改善AD小鼠模型中的认知功能,并在人体试验中减缓衰退,尽管临床益处尚未完全确定.
- 一些老年人保持认知功能,尽管高Aβ斑块负载,挑战Aβ的核心因果作用.
- 临床前研究表明,通过降低或操纵,并通过增强大脑储备机制,可以减轻Aβ毒性.
- 低强度超声波在不降低Aβ水平的情况下改善了Aβ沉积小鼠的认知能力.
结论:
- 在阿尔茨海默病中,Aβ斑块负载和认知障碍之间存在分离关系.
- 针对tau或增强大脑储备的治疗策略可能为以Aβ为中心的疗法提供替代或补充方法.
- 像低强度超声波这样的神经调节技术为阿尔茨海默氏症的认知改善提供了一个有希望的途径,独立于Aβ清除.
相关概念视频
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
114
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
114
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456


